目的 探讨肾康注射液联合重组人促红素注射液治疗慢性肾功能衰竭合并肾性贫血的临床疗效。方法 选取2014年5月-2016年3月在徐州市肿瘤医院肾内科接受治疗的80例慢性肾衰竭合并肾性贫血的患者为研究对象，随机分为对照组和治疗组，每组各40例。对照组患者皮下注射重组人促红素注射液（CHO细胞），50 IU/（kg·次^-1），2次/周，同时口服常规造血原料。治疗组在对照组的基础上静脉注射肾康注射液100 mL，1次/d。两组患者均治疗3个月。观察两组的临床疗效，同时比较治疗后1、2、3个月血常规、铁蛋白、相关激素、肾功能指标和药物不良反应。结果 治疗后，对照组、治疗组总有效率分别为85.0%、97.5%。两组总有效率比较差异具有统计学意义（P<0.05）。治疗1、2、3个月，两组的红细胞（RBC）、血红蛋白（HGB）、血细胞比容（HCT）和铁蛋白（SF）水平均较治疗前升高（P<0.05）；且治疗组的这些指标优于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗1、2、3个月，两组的电解质钙（Ca）水平较治疗前升高，甲状旁腺激素（PTH）、电解质磷（P）水平较治疗前降低（P<0.05）；且治疗组这些观察指标的改善程度明显优于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗1、2、3个月，两组的血尿素氮（BUN）、血肌酐（Scr）、血尿酸水平均较治疗前降低（P<0.05）；且治疗组这些观察指标的改善程度明显优于同期对照组，两组比较差异具有统计学意义（P<0.05）。治疗组患者不良反应发生率明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 肾康注射液联合重组人促红细胞生成素治疗慢性肾功能衰竭合并肾性贫血具有较好的临床疗效，可增强对铁的吸收，明显改善肾功能，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Shenkang Injection combined with recombinant human erythropoietin in treatment of chronic renal failure with renal anemia. Methods Patients (80 cases) with chronic renal failure and renal anemia in Department of Nephrology in Xuzhou Tumor Hospital from May 2014 to March 2016 were randomly divided into control group and treatment group, and each group had 40 cases. Patients in the control group were ih administered with Recombinant Human Erythropoietin Injection, 50 IU/(kg·time), twice weekly, and also were given conventional hematopoietic raw materials. Patients in the treatment group were iv administered with Shenkang Injection 100 mL on the basis of the control group, once daily. Patients in two groups were treated for 3 months. After treatment for 1, 2, and 3 months, the clinical efficacies were evaluated, andblood tests, ferritin, hormones, renal function, and adverse reaction of drug in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.0% and 97.5%, respectively, and there was difference between two groups (P<0.05). After treatment for 1, 2, and 3 months, levels of RBC, HGB, HCT, and SF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment for 1, 2,and 3 months, levels of Ca in two groups were significantly increased, but levels of PTH and P in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment for 1, 2, and 3 months, levels of BUN, Scr and serum uric acid in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).The incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Shenkang Injection combined with recombinant human erythropoietin has clinical curative effect in treatment of chronic renal failure with renal anemia, and can enhance the absorption of iron, improve renal function, which has a certain clinical application value.